Nykredit A S Acquires Shares of 282,407 Stryker Corporation $SYK

Nykredit A S bought a new position in shares of Stryker Corporation (NYSE:SYK) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 282,407 shares of the medical technology company’s stock, valued at approximately $88,913,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. InTrack Investment Management Inc raised its position in shares of Stryker by 9.8% in the 2nd quarter. InTrack Investment Management Inc now owns 5,770 shares of the medical technology company’s stock valued at $1,817,000 after purchasing an additional 517 shares in the last quarter. B. Metzler seel. Sohn & Co. AG grew its position in shares of Stryker by 121.3% during the second quarter. B. Metzler seel. Sohn & Co. AG now owns 175,636 shares of the medical technology company’s stock worth $55,297,000 after buying an additional 96,281 shares in the last quarter. Coppell Advisory Solutions LLC acquired a new stake in shares of Stryker during the second quarter worth approximately $1,005,000. Natural Investments LLC increased its stake in shares of Stryker by 1.2% in the second quarter. Natural Investments LLC now owns 2,789 shares of the medical technology company’s stock worth $878,000 after buying an additional 34 shares during the last quarter. Finally, Banco de Sabadell S.A raised its holdings in Stryker by 1.3% in the second quarter. Banco de Sabadell S.A now owns 5,843 shares of the medical technology company’s stock valued at $1,848,000 after acquiring an additional 74 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other news, insider Dylan Bram Crotty sold 441 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Debra King sold 826 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. This represents a 11.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 351,267 shares of company stock worth $118,197,701 over the last ninety days. Company insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. BMO Capital Markets started coverage on shares of Stryker in a research note on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price objective on the stock. Piper Sandler cut their target price on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Royal Bank Of Canada decreased their price target on Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Finally, Argus set a $370.00 price objective on Stryker in a research note on Thursday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and an average price target of $386.28.

Stryker Stock Down 1.7%

SYK stock opened at $312.10 on Thursday. The firm has a market cap of $119.71 billion, a price-to-earnings ratio of 32.34, a PEG ratio of 1.99 and a beta of 0.76. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The firm has a fifty day moving average price of $329.60 and a two-hundred day moving average price of $330.33. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same period last year, the firm posted $3.13 EPS. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts predict that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Director Mary Brainerd purchased additional Stryker shares on September 2, increasing her personal stake. Insider buying can signal confidence in the company’s valuation and outlook, although the purchase alone is unlikely to materially change earnings expectations. Stryker Insider Makes Bold New Move With Fresh Share Purchase
• Positive Sentiment: Stryker received FDA De Novo authorization for SportSuite Vision, its surgical application for Apple Vision Pro, and completed the first reported hip arthroscopy using the system. The technology could strengthen Stryker’s digital-surgery and orthopedic innovation offerings, though commercial adoption remains to be demonstrated. Stryker introduces FDA-authorized surgical application for Apple Vision Pro
• Positive Sentiment: Stryker agreed to acquire ZuriMED, adding the FiberLocker System and expanding its shoulder-care and rotator-cuff portfolio. The deal could broaden Stryker’s orthopedic product lineup and growth opportunities. Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio
• Neutral Sentiment: Analysts remain broadly optimistic about Stryker’s longer-term prospects even as the shares have underperformed the broader market. The company’s latest reported quarter exceeded earnings expectations, but its valuation remains relatively elevated, which can increase sensitivity to growth concerns. Is Stryker Stock Underperforming the Nasdaq?
• Negative Sentiment: The recent underperformance suggests investors may be focused more on valuation, execution, and market-wide factors than on the new product announcements. The ZuriMED transaction also introduces integration and spending risks, with financial terms and its near-term earnings contribution not specified in the available reports.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.